Candel Therapeutics Gets FDA Nod for Prostate Cancer Treatment
Candel Therapeutics announced that its lead immunotherapy candidate, CAN-2409, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA...
Athena GTX Halberd Study Updates & Telemedicine Partnership
Halberd Corporation, in collaboration with Athena Telemedicine Partners, reports positive clinical results for its patent-pending LDX compound in treating...
Syncromune® Announces Publication of Abstract on Sync-T® Therapy at ASCO 2025
Syncromune’s Phase 1 clinical trial of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) showed an...
CHMP Positive on Mirdametinib for NF1-PN Treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional marketing authorization for mirdametinib, a...
Briacell Showcases Positive ASCO 2025 Data
BriaCell Therapeutics Corp. announced positive Phase 2 clinical trial data for its Bria-IMT™ immunotherapy in metastatic breast cancer, demonstrating...
Iovance Announces Five-Year Amtagvi® Results in Melanoma Patients at ASCO
Iovance Biotherapeutics announced five-year follow-up data from the Phase 2 C-144-01 trial of its tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi...
Petosemtamab Plus Pembro Show Robust Efficacy in 1L PD-L1+ R/M HNSCC
Merus N.V. announced interim phase 2 trial data for petosemtamab combined with pembrolizumab in treating head and neck squamous...
ImCheck AML Therapy Shows High Remission at ASCO 2025
ImCheck Therapeutics announced positive interim results from its Phase I/II EVICTION study of ICT01, a novel γ9δ2 T-cell activator,...
Taiho Pharma Zipalertinib Shows Promise in Pivotal Phase 2b Trial
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive Phase 2b results from the REZILIENT1 trial of zipalertinib, an...
Adagene Announces Updated Data from Phase 1b/2 Study of Muza in Colorectal Cancer at ASCO
Adagene Inc. released updated Phase 1b/2 clinical trial data for ADG126, a novel anti-CTLA-4 antibody, combined with pembrolizumab in...